Former Chief Executive Officer (7) · UroGen Pharma Ltd. (URGN)

Ron Bentsur

A named executive officer of UroGen Pharma in every fiscal year CompBrief holds from FY2016 to FY2019. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2019

$8,138

Salary $5,812Stock awards $0

FY2018: $5,950,112

5th of 5 named executive officers at UroGen Pharma by FY2019 total.

5 named officers on file for UroGen Pharma, FY2019

Ron Bentsur’s pay file — $29

  • 4 fiscal years of pay, line by line
  • 1 equity grant, each cited to its filing
  • URGN’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how UroGen Pharma’s whole pay program stands against its peers

  • UroGen Pharma’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on URGN→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 29, 2020 (DEF 14A).

Free

Get Ron Bentsur’s full pay file as a PDF — free

More than this page: up to 10 years of Ron’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Ron Bentsur compensation by year

UroGen Pharma Summary Compensation Table · all 4 fiscal years held
In US dollars, as UroGen Pharma reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2016FY2017FY2018FY2019
Salary$312,960$414,252$610,200$5,812
Bonus$0$0$0$0
Stock awards$0$0$0$0
Option awards$0$1,244,448$1,739,588$0
Non-equity incentive$0$225,973$334,000$0
Pension and deferred compensation$0$0$0$0
All other$86,065$87,667$3,266,324$2,326
Total$399,025$1,972,339$5,950,112$8,138

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: UroGen Pharma Ltd. DEF 14A filed April 29, 2020, accession 0001564590-20-019410, and prior-year filings. Open the filing on EDGAR.

How this page was built: the UroGen Pharma Ltd. filed document, accession 0001564590-20-019410. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2020.

$399K
$2.0M
$6.0M
$8K
FY16
FY17
FY18
FY19
SalaryNon-equity incentiveOption awardsAll other

Equity holdings

unvested awards at FY2018 year-end
TypeUnvested unitsValue at year-endExercise price
Option41,067—$0.00
Option40,000—$19.55
Option34,723—$43.67

Per the Outstanding Equity Awards at Fiscal Year-End table in UroGen Pharma Ltd.'s FY2018 proxy; value at the fiscal year-end close, as the company printed it.

UroGen Pharma’s named executive officers, FY2019

as the company reported each
Named executive officerRoleFY2019 total
Elizabeth BarrettChief Executive Officer$25,900,823
Peter PfreundschuhChief Financial Officer (8)$1,346,791
Stephen MullennixChief Operating Officer (9)$1,346,512
Mark SchoenbergChief Medical Officer$800,908
Ron Bentsur · this pageFormer Chief Executive Officer (7)$8,138

The full UroGen Pharma compensation record

free company brief

This page is one person within UroGen Pharma's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the UroGen Pharma proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are UroGen Pharma's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Ron Bentsur's compensation dossier · One-time report. No refunds.